Rhythm announced that it has enrolled the first patient with hypothalamic obesity in Part C of its Phase 1 trial evaluating RM-718, a weekly-administered melanocortin-4 receptor agonist.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Strong Future Performance and Market Adoption Drive Buy Rating for Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Advances in Hypothalamic Obesity Treatment with LB54640 Study
- Rhythm Pharmaceuticals’ Promising Phase 2 Study on LB54640 for Hypothalamic Obesity
- Rhythm Pharmaceuticals price target raised to $105 from $92 at Canaccord
- Promising Potential of Rhythm Pharmaceuticals’ Treatments for Hypothalamic Obesity Drives Buy Rating